The global chronic kidney disease market size was estimated to be USD 34.63 billion in 2023 and is expected to reach at USD 70.82 billion by 2034 with a CAGR of 6.72% during the forecast period 2024-2034. Surge in prevalence of chronic kidney disease, growing technological advancements in diagnostic tests, rising need for early detection, increasing technologically advanced products & diagnostics tests to early detect chronic kidney disease, surge in government initiatives towards CKD, growing focus on development of drugs, and rising launch of innovative advanced tools are some of the key factors boosting the market growth.
Rising launch of innovative advanced tools is predicted to boost the market growth during the forecast period. Key factors contributing to CKD include conditions such as diabetes, high blood pressure (hypertension), and specific kidney infections or ailments. Chronic kidney disease (CKD) generally develops gradually and advances through various stages, depending on the degree of kidney functionality. Therefore, the treatment of chronic kidney disease (CKD) encompasses a variety of medical approaches and tactics designed to oversee and decelerate the advancement of kidney impairment and its related complications. For instance, in March 2022, Nova Biomedical has introduced the Nova Max Pro Creatinine/eGFR Meter System, a novel tool designed to enhance kidney care by facilitating kidney function screening and the early identification of kidney disease in non-hospital point-of-care settings. This system features an uncomplicated meter and a creatinine biosensor that measures blood creatinine and computes the estimated glomerular filtration rate (eGFR) from a small 1.2 microliter blood sample obtained via a fingertip prick. This process takes only 30 seconds.
By product, diagnosis was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to rising prevalence of chronic kidney disease, escalating technologically advanced diagnostic products, increasing demand for early diagnosis of the diseases, surge in government initiative for spreading awareness regarding CKD. Additionally, treatment is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, surge in number of clinical trial procedures, and increasing approvals by regulatory bodies. For instance, in July 2022, GlaxoSmithKline's (GSK) submission of Daprodustat, an oral inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), has been acknowledged by Health Canada. This submission is aimed at considering daprodustat as a possible treatment for individuals affected by anemia associated with chronic kidney disease (CKD).
By route of administration, oral was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to increasing improvements in medical industry, growing demand for self-administration, and rising approvals by regulatory bodies. For instance, in March 2022, Zydus Lifesciences has received approval from the Drug Controller General of India (DCGI) for its New Drug Application (NDA) concerning Oxemia. This marks a significant milestone as Oxemia is a pioneering oral remedy within India for managing anemia linked to chronic kidney disease (CKD). Additionally, intravenous is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of chronic kidney disease and increasing advancement in drug delivery systems.
By end-user, hospitals was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to rising number of hospitals, growing number of patients suffering from chronic kidney diseases, and increasing launch of novel drugs by market players. For instance, in March 2022, In the United States market, Lupin has introduced Sevelamer Hydrochloride tablets, designed for addressing hyperphosphatemia among patients diagnosed with chronic kidney disease (CKD). Additionally, diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the growing number of people suffering from kidney disorders, rising investment for healthcare infrastructure, and increasing adoption of technologically advanced diagnostic devices.
Europe region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic kidney diseases, growing healthcare infrastructure, increasing technologically advanced diagnostic tests, rising approvals by regulatory bodies. For instance, in November 2022, ProKidney Corp. has shared the news that the United Kingdom's MHRA has given the green light to the proact 1 (REGEN-006) Phase 3 study protocol for their investigational candidate, REACT®, following the submission of a clinical trial application. This approval in the UK follows a prior approval by the FDA in the United States for the proact 1 Phase 3 study protocol. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising government awareness initiatives, growing research & development activities, increasing demand for quality diagnostic testing & advanced treatments, and surge in introduction of innovative drugs. For instance, in August 2022, In India, Bayer has introduced a finerenone medication for the treatment of chronic kidney disease (CKD) connected to type-2 diabetes.
Rising launch of innovative advanced tools is predicted to boost the market growth during the forecast period. Key factors contributing to CKD include conditions such as diabetes, high blood pressure (hypertension), and specific kidney infections or ailments. Chronic kidney disease (CKD) generally develops gradually and advances through various stages, depending on the degree of kidney functionality. Therefore, the treatment of chronic kidney disease (CKD) encompasses a variety of medical approaches and tactics designed to oversee and decelerate the advancement of kidney impairment and its related complications. For instance, in March 2022, Nova Biomedical has introduced the Nova Max Pro Creatinine/eGFR Meter System, a novel tool designed to enhance kidney care by facilitating kidney function screening and the early identification of kidney disease in non-hospital point-of-care settings. This system features an uncomplicated meter and a creatinine biosensor that measures blood creatinine and computes the estimated glomerular filtration rate (eGFR) from a small 1.2 microliter blood sample obtained via a fingertip prick. This process takes only 30 seconds.
By product, diagnosis was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to rising prevalence of chronic kidney disease, escalating technologically advanced diagnostic products, increasing demand for early diagnosis of the diseases, surge in government initiative for spreading awareness regarding CKD. Additionally, treatment is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, surge in number of clinical trial procedures, and increasing approvals by regulatory bodies. For instance, in July 2022, GlaxoSmithKline's (GSK) submission of Daprodustat, an oral inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), has been acknowledged by Health Canada. This submission is aimed at considering daprodustat as a possible treatment for individuals affected by anemia associated with chronic kidney disease (CKD).
By route of administration, oral was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to increasing improvements in medical industry, growing demand for self-administration, and rising approvals by regulatory bodies. For instance, in March 2022, Zydus Lifesciences has received approval from the Drug Controller General of India (DCGI) for its New Drug Application (NDA) concerning Oxemia. This marks a significant milestone as Oxemia is a pioneering oral remedy within India for managing anemia linked to chronic kidney disease (CKD). Additionally, intravenous is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of chronic kidney disease and increasing advancement in drug delivery systems.
By end-user, hospitals was the highest revenue-grossing segment in the global chronic kidney disease market in 2023 owing to rising number of hospitals, growing number of patients suffering from chronic kidney diseases, and increasing launch of novel drugs by market players. For instance, in March 2022, In the United States market, Lupin has introduced Sevelamer Hydrochloride tablets, designed for addressing hyperphosphatemia among patients diagnosed with chronic kidney disease (CKD). Additionally, diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to the growing number of people suffering from kidney disorders, rising investment for healthcare infrastructure, and increasing adoption of technologically advanced diagnostic devices.
Europe region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of chronic kidney diseases, growing healthcare infrastructure, increasing technologically advanced diagnostic tests, rising approvals by regulatory bodies. For instance, in November 2022, ProKidney Corp. has shared the news that the United Kingdom's MHRA has given the green light to the proact 1 (REGEN-006) Phase 3 study protocol for their investigational candidate, REACT®, following the submission of a clinical trial application. This approval in the UK follows a prior approval by the FDA in the United States for the proact 1 Phase 3 study protocol. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising government awareness initiatives, growing research & development activities, increasing demand for quality diagnostic testing & advanced treatments, and surge in introduction of innovative drugs. For instance, in August 2022, In India, Bayer has introduced a finerenone medication for the treatment of chronic kidney disease (CKD) connected to type-2 diabetes.
Segmentation: Chronic Kidney Disease Market Report 2022 - 2033
Chronic Kidney Disease Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
Diagnosis
- Imaging Tests
- Urine Tests
- Blood Tests
- Others
Treatment
- Dialysis
- Drug Class
- Angiotensin-II Receptor Blockers
- Diuretics
- ACE Inhibitors
- Others
- Others
Chronic Kidney Disease Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Intravenous
- Subcutaneous
Chronic Kidney Disease Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Diagnostic Laboratories
- Hospitals
- Others
Chronic Kidney Disease Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Chronic Kidney Disease Market: Product Estimates & Trend Analysis
8. Chronic Kidney Disease Market: Route of Administration Estimates & Trend Analysis
9. Chronic Kidney Disease Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Chronic Kidney Disease Market
12. Europe Global Chronic Kidney Disease Market
13. Asia Pacific Global Chronic Kidney Disease Market
14. Latin America Global Chronic Kidney Disease Market
15. MEA Global Chronic Kidney Disease Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- B. Braun SE
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca plc
- Fresenius SE and Co. KGaA
- Baxter International Inc.
- Johnson & Johnson
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Becton
- Dickinson and Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 34.63 Billion |
| Forecasted Market Value ( USD | $ 70.82 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
